KIMS Approves FY26 Audited Results, Appoints Cost Auditors, and Expands Senior Management
KIMS' Board approved FY26 audited standalone and consolidated results for the quarter ended March 31, 2026. Cost Auditors were appointed for FY27. New Senior Management Personnel, including a CFO and Company Secretary, were identified. Mr. Adwik Bollineni was redesignated to Executive Director. The 24th AGM is set for August 27, 2026.
The approval of financial results is a routine event. However, the appointment of cost auditors, changes in senior management personnel, and redesignation of a director are significant corporate actions that can impact governance and operational oversight, warranting a medium impact assessment.
The announcement pertains to the approval of audited financial results, appointment of cost auditors, and changes in senior management and directorship. While these are important corporate actions, they do not inherently suggest a positive or negative shift in the company's performance or outlook based solely on this disclosure.
Krishna Institute of Medical Sciences Limited (KIMS) announced the outcome of its Board Meeting held on May 15, 2026. The Board approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The company also appointed M/s. Sagar & Associates as Cost Auditors for FY 2026-27, with their remuneration to be recommended to the members at the ensuing AGM.
Furthermore, KIMS identified new Senior Management Personnel (SMP) with immediate effect: Mr. Sachin Ashok Salvi as Chief Finance Officer, Mrs. Nagajayanthi J.R as Company Secretary & Compliance Officer, and Mr. Bhaskar Reddy R.K as Chief Risk Officer & Chief Internal Audit. The Board also approved the re-designation of Mr. Adwik Bollineni from Non-Executive & Non-Independent Director to Executive & Non-Independent Director.
The 24th Annual General Meeting (AGM) of the Company is scheduled to be held on Thursday, August 27, 2026. The financial results and audit reports are available on the company's website and the websites of BSE and NSE.
What to do with a filing like this
Krishna Institute of Medical Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krishna Institute of Medical Sciences Limited. Read the original for the full detail.